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ABSTRACT
This study investigated whether regular aerobic exercise training could prevent the
dysregulation of autonomic cardiovascular (CV) control in a streptozotocin (STZ)diabetes model designed to represent clinical type 1 diabetes mellitus (T1DM). Rats were
divided into control (C), control exercise (CX), diabetic (D) and diabetic exercise (DX)
groups. Baroreflex sensitivity (BRS), heart rate variability (HRV) and vascular
sympathetic

tone

(VST)

were

measured

following

10

weeks

of

exercise.

Parasympathetic-mediated bradycardia BRS was reduced in D compared to C and DX
(p<0.05). The HF (parasympathetic) HRV was reduced in D compared to CX and DX
(p<0.05) and the LF/HF ratio (sympathetic HRV) was elevated in D compared to all other
groups (p<0.05). The VST was increased in D compared to all other groups (p<0.05).
Diabetes caused a CV autonomic imbalance, which was prevented by exercise training.
Thus, this model paralleled clinical T1DM and demonstrated that exercise can prevent
autonomic dysfunction.

Keywords: type 1 diabetes, aerobic exercise, diabetic autonomic neuropathy,
cardiovascular autonomic neuropathy, sympathetic overactivity, heart rate variability,
baroreflex sensitivity, parasympathetic nervous system
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CHAPTER 1
1.1 Introduction
Type 1 diabetes mellitus (T1DM) is an idiopathic autoimmune disease that
results in the destruction of pancreatic β cells and subsequently, the inability to
produce endogenous insulin (4, 7, 144). This results in chronic hyperglycemia and
imbalances of fat, protein, and carbohydrate metabolism that lead to progressive
complications, such as: retinopathy, nephropathy, neuropathy and increased risk of
microvascular and macrovascular disease (4, 7, 24). These complications can be so
severe that, even with insulin therapy, a child diagnosed with diabetes at 10 years of
age will lose an average of 19 years of life due to the disease (97). Epidemiological
studies have shown that T1DM incidence is continuously rising in both high and low
incidence populations; particularly, in the 15 years of age and younger demographic
(63, 99, 163). For example, Onkamo et al. (99) reported that the global incidence rate
of the under 15 demographic from 1960 to 1996 increased at 3% per year. The
DiaMond Project Group (26), a multinational effort to investigate and monitor the
incidence patterns of childhood type 1 diabetes, reported a yearly global increase in
incidence of 3.4% for the years 1995 to 1999. In Europe it has been predicted that by
2020 the number of children under the age of 5 afflicted with T1DM will double and
the number of cases for children under the age of 15 will increase by 70% (104).
Clearly, this demonstrates that T1DM is a problem that is continuously growing in
prevalence and importance. Also of importance are the financial costs of T1DM on
patients and society at large (130). In fact, it was found that patient costs for
individuals with T1DM are disproportionately higher than costs for those with type 2
diabetes mellitus (T2DM) (142). Furthermore, the societal costs of T1DM in the USA
and the UK are estimated at $14.4 billion and $3 billion per year, respectively (46,
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142). In light of such profound health and economic impacts, understanding the
predictors, onset and treatment of T1DM has been a focus of extensive investigation;
yet, a substantial amount about the disease and its complications remains to be
elucidated. Although it has been long understood that exercise can generate beneficial
health outcomes, more recently and increasingly, exercise is being regarded as a
therapy and is being prescribed by physicians as medicine (123, 128). The benefits of
exercise in the prevention and treatment of T1DM-related complications has been
well documented (36, 105, 112). In particular, diabetic autonomic neuropathy (DAN)
is known to be one of the earliest complications of diabetes which not only precludes
a variety of related complications but is also directly linked to increased mortality
(30, 40, 100, 149). Thus, the ability of exercise therapy to reduce DAN is a research
focus of great importance (9, 18, 105, 150). This chapter will provide an overview of
T1DM onset and its mediation of neuropathy, the function of the autonomic nervous
system and its regulation of the cardiovascular system, how neuropathy leads to
autonomic and cardiovascular dysfunction and the efficacy of exercise in mitigating
this dysfunction.

1.2 Etiology of Type 1 Diabetes Mellitus
Susceptibility to T1DM is determined by both genetic and environmental
factors (7, 31, 58, 144). The genetic basis of the disease is strongly exhibited by
studies of monozygotic and dizygotic twins. It has been found that monozygotic twins
can demonstrate over a 50% concordance rate of T1DM, which is far greater than the
concordance between dizygotic twins (50). Due to the fact that monozygotic twins
share the same DNA and developmental environment, whereas dizygotic twins have
non-identical DNA but also share the same developmental environment, it can be
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concluded that the difference in concordance between the two types of twins is
resultant of a genetic influence (31). Through such twin studies, as well as familial
linkage studies, it has been established that the human leukocyte antigen (HLA)
encoding genes, which code for many different components of the immune system,
are the major factors conferring genetic susceptibility to T1DM (24, 31, 48, 50).
Although a high percentage of T1DM susceptibility can be attributed to a genetic
component, even at 50% concordance, there remain at least equally substantial nongenetic factors that are involved in the manifestation of T1DM.
Environmental factors, including viral infections, diet, growth, toxins and
stress, have been implicated in the pathogenesis of T1DM (3). D’Angeli et al. (28)
provide evidence for the “hygiene hypothesis” by demonstrating that a clean
environment during childhood decreases antigenic stimulation and results in a greater
vulnerability to developing T1DM.

Further evidence of an environmental

determinant of T1DM is the apparent role of geography and climate in its prevalence.
In both Europe and North America there is a north to south, high to low, gradient of
incidence (58, 144). In accordance with a climatic influence, a lower incidence of
T1DM during warm seasons than cold seasons has been observed within populations
(58, 68). Although these genetic, regional and climatic insights provide evidence of
risk factors for developing T1DM, they are not necessarily predictors of great utility.
The environmental factors may be correlated with T1DM but most cannot realistically
be avoided or managed, whereas the genetic factors alone do not yield disease onset;
as evidenced by the finding that, at most, only 10% of individuals with the highest
risk susceptibility genes actually become afflicted with T1DM (146).
The most effective predictors of T1DM are a complement of autoantibodies
that can be detected years before the disease develops; in fact, they can even be
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detected during infancy (12, 61). The autoantibodies that predict T1DM are: islet cell
antibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase
antibodies (GADA) and protein tyrosine phosphatase-2 antibodies (IA-2A) (71, 80).
These autoantibodies direct the infiltration of immune cells, mostly T cells, to the
islets and facilitate their inflammation and the destruction of β cells (19, 25, 71). It
has been observed that the detection of two or more of these autoantibodies in
relatives of T1DM patients has a 90% predictive value for their eventual development
of T1DM (147). In the general population, marginally elevated levels of 3 to 4
autoantibodies indicates a risk of roughly 60% for the development of T1DM (12).
Despite the predictive value of autoantibody detection, no autoantibody based
treatments exist to avert the onset of T1DM (25). Therefore, for now, the only way to
delay or prevent T1DM associated morbidity and mortality is to understand and
ameliorate the progression of the disease-related complications (4, 25, 80). However,
it has been suggested that exercise could ameliorate the severity of autoantibody
mediated inflammation and subsequently, reduce T1DM initiation and progression
(66).

1.3 Pathogenesis of Neuropathy in T1DM
The neurological complications of T1DM are understood to arise from either a
metabolic etiology, a vascular etiology or a combination of both (30, 41, 137, 156).
However, the pathology of metabolism and vasculature in T1DM, as well as the wider
breadth of complications that develop, arises primarily due to chronic hyperglycemia
(24, 41, 149). Indeed, the duration and severity of hyperglycemia have both been
indicated as predictors of the degree of diabetic neuropathy (30, 41). Fittingly then,
advanced glycation end-products (AGEs), which are formed when hyperglycemia
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leads to irreversible binding of glucose molecules to intracellular and extracellular
proteins, have been implicated as a causative link between vascular and metabolic
dysfunction in T1DM (41).
The metabolic factors, whose dysfunction primarily contributes to diabetic
neuropathy, are many. For example, T1DM leads to increased polyol pathway activity
and decreased myo-inositol, which are associated with decreased nerve conduction
velocity (30, 41, 137). It also causes decreased nerve Na/K ATPase activity, the
function of which is necessary to maintain the transmembrane ionic gradient required
for electrical impulse conduction (41, 137). Further, T1DM is associated with
decreased synthesis and transport of axonal proteins, which are supplied from the cell
body to maintain structural and functional integrity of the axon (41, 87, 137) and
diminished incorporation of glycolipids and amino acids into myelin, thereby
reducing axon insulation and conduction velocity (30, 41, 139). T1DM also leads to
decreased nerve protein kinase C (PKC) activity, which can further reduce Na/K
ATPase activity (137). Dyslipidemia, consisting of increased triglycerides, increased
low-density lipoprotein and decreased high-density lipoprotein, is a metabolic factor
that contributes to neuropathy via the atherosclerotic impairment of the vasculature
(30, 41, 107).
Vascular factors that contribute to diabetic neuropathy mostly involve
pathology of the endoneurial capillaries (92, 152). These vascular impairments
include: basement membrane thickening and endothelial cell swelling and
proliferation, resulting in reduced luminal diameter, decreased nerve blood flow and
endoneurial hypoxia (41, 83, 143); degeneration of pericytes, which are integral for
maintaining endothelial cell function at the blood-nerve barrier (41, 129); and
ultimately, endoneurial capillary atherosclerosis, which leads to the dysregulation of
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nutrient exchange between axons and blood vessels across the endoneurium (30, 41,
129, 143). There is also evidence that hyperglycemia can have tissue-specific,
bidirectional effects on PKC activity (138). While hyperglycemia decreases PKC
activity in the nerve as mentioned above, it also becomes overactive in vascular
endothelium and leads to increased endothelial permeability, the dysregulation of
endothelial-derived vasodilator nitric oxide (NO) and thus, diminished blood flow
(127, 138).
Despite these metabolic and vascular factors often being considered discrete
etiologies of diabetic neuropathy, it is more likely that they arise concomitantly and
share protein glycation as their common cause (see Figure 1.1) (30, 41). For example,
glycation of antioxidant enzymes hinders their ability to remove reactive oxygen
species (ROS). This results in the accumulation of ROS that damage membranes,
cellular proteins and DNA, all of which contribute to neuropathic progression (41).
Glycation of the nitric oxide synthase (NOS) enzyme is likely a mechanism by which
NO production is decreased, driving the vascular dysfunction described above (41,
138). Also, glycated elastin and collagen in the endothelium can restrict access of NO
to the smooth muscle, further inhibiting NO-mediated vasodilation, reducing nerve
blood flow and nerve oxygenation (41). The manifestation of AGEs in the basement
membrane, elastic lamina and endothelial cells of the blood vessels causes
macrophage infiltration, which release macrophage-derived growth factors , leading
to smooth muscle proliferation and atherogenesis (41). Due to evidence that
inflammatory cytokines also cause vascular damage by inducing excessive ROS, it is
plausible that AGE-mediated inflammation is the primary cause of neurovascular
dysfunction in diabetic neuropathy (36, 134). AGE levels in the endoneurium and
associated microvessels have been observed to correlate with the degree of axonal
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atrophy in nerve biopsies; with AGE immunoreactivity detected in 90% of peripheral
nerves of diabetics compared to a complete absence of AGEs in controls (91).
Whether or not AGEs can be said to underlay both the metabolic and vascular causes
of neuropathy, they certainly do represent a link between them. Ultimately,
hyperglycemia-mediated AGEs, metabolic dysregulation and vascular dysfunction are
all fundamental to nerve dysfunction and degeneration in T1DM.

1.4 The Autonomic Nervous System and Mechanisms of Autonomic Cardiovascular
Regulation
The autonomic nervous system (ANS) is a network of efferent and afferent
nerves linked to structures of the central nervous system (CNS) that, together, govern
the motor control of visceral organs (40, 76). Since targets of the ANS include
multiple endocrine organs, the cardiovascular (CV) system and regions of CNS, the
ANS is a powerful regulator of homeostasis throughout the entire body (76, 124). The
ANS differentially regulates these systems by using two antagonistic branches, the
sympathetic nervous system (SNS) and the parasympathetic nervous system (PSNS),
which mutually inhibit one another (116). The main neurochemical difference
between the SNS and PSNS is the neurotransmitters involved in signaling to the target
organs. Preganglionic neurons of both branches utilize acetylcholine as their primary
neurotransmitter, whereas the postganglionic neurons of the PSNS emit primarily
acetylcholine and the postganglionic neurons of the SNS release primarily
norepinephrine (76, 116). The use of these different neurotransmitters underlies the
antagonistic physiological actions of the two branches of the ANS (76, 116). To
understand the discrete roles of the SNS and PSNS in controlling bodily functions, the
mnemonics “fight or flight” and “rest and digest” are used, respectively (116, 149).
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The SNS directs oxygen and energy toward organ systems that are recruited in
stressful or active situations; for example, it acts to increase heart rate (HR) and
decrease enteric motility. The PSNS, on the other hand, promotes conservation and
restoration of energy and so, stimulates functions that are more useful at rest while
inhibiting others; for example, it decreases blood pressure (BP) and facilitates the
excretion of waste (76, 116). When functioning properly, these two branches maintain
chronic homeostasis of visceral organ function (116).
One such autonomically-mediated mechanism of homeostasis is the regulation
of CV function by the baroreflex (see Figure 1.2). Afferent arterial baroreceptors are
stretch-sensitive mechanoreceptors located in the aortic arch, carotid sinus and
elsewhere in the vasculature that send frequency coded signals to the brainstem in
order to signal increases and decreases in BP (40). Once these signals arrive at the
brainstem they are processed by several structures that govern the efferent
sympathetic and parasympathetic output to the heart, the vasculature, kidneys and
other visceral organs (40, 116). The four major brain regions involved in processing
these signals include the hypothalamus and three regions of the brainstem: the rostral
ventrolateral medulla (RVLM), the caudal ventrolateral medulla (CVLM) and the
nucleus of the solitary tract (NTS) (40, 76, 116). When a rise in BP above the set
physiological range occurs, the baroreceptors fire rapidly and stimulate the NTS. The
NTS in turn stimulates the CVLM, which provides inhibitory input to the RVLM.
Since the RVLM has excitatory input to sympathetic preganglionic neurons in the
intermediolateral (IML) column of the thoraco-lumbar spinal cord, when
baroreceptors fire the RVLM, and by extension sympathetic outflow, is inhibited and
the autonomic balance shifts towards greater parasympathetic activity; the outcome of
which is reduced HR and the restoration of BP to the physiological range (8, 40, 116).
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Alternatively, when arterial pressure declines below the set physiological range,
baroreceptor firing decreases, removing the stimulation of the NTS and CVLM and
disinhibiting the RVLM, resulting in increased sympathetic outflow, HR and again,
the restoration of BP to the physiological range (40, 116).
The baroreflex also has an important influence on total peripheral resistance
(TPR); which is the resistance of all peripheral vasculature in the systemic circulation
(145). Peripheral resistance and the variables that influence it can be described by
Poiseuille’s law, 𝑅 =

𝛥𝑃
𝑄

; where R is resistance, ΔP is the change in pressure between

two points and Q is the blood flow, which is equivalent to cardiac output (90).
8ɳ𝐿

Resistance can also be represented as 𝑅 = 𝜋r4; where ɳ is the viscosity of the fluid, L

is the length of the vessel, and r is the radius (90). Blood pressure and blood flow
(cardiac output) are acutely regulated by the baroreflex (77). However, beat-to-beat
changes in TPR are difficult to measure and thus, most studies examine feedback
control of HR as opposed to TPR when assessing the baroreflex (10).
The paraventricular nucleus (PVN) of the hypothalamus also modulates
sympathetic outflow (11, 21, 40). The PVN receives inputs from circulating hormones
and molecules (such as norepinephrine and glucose), visceral receptors that detect

osmolarity and blood volume and other regions of the brain (11). The PVN has many
complex effector subnuclei but its effects can be summed through its three major
connections. The magnocellular neurons of the PVN are large cells that interact with
the posterior pituitary to release oxytocin and vasopressin (also known as antidiuretic
hormone, ADH; a vasoconstrictor and mediator of water absorption in the kidneys)
into the blood (113). The medial parvocellular neurons synthesize corticotropin
releasing hormone (CRH), which stimulates the release of adrenocorticotropic
hormone (ACTH) from the anterior pituitary, which then acts on the adrenal cortex to
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stimulate aldosterone (a mediator of water retention in the kidneys)and cortisol
production (which stimulates gluconeogenesis in the liver); this constitutes what is
known as the hypothalamo-pituitary-adrenocortical (HPA) axis (11, 125). Another
subset of parvocellular PVN neurons have direct connections to the RVLM in the
brainstem and the IML in the spinal cord (8). Thus, these PVN neurons can directly
and indirectly influence sympathetic nerve activity via inputs to preganglionic
sympathetic neurons and by modulating RVLM activity (8). Indeed, it has been
demonstrated that sympathoexcitation is elicited through the PVN in response to a
drop in blood volume, without a drop in pressure, via the activation of both RVLM
and ILM connected neurons (8). Conversely, the autonomic neurons of the PVN have
been reported to selectively decrease renal sympathetic activity and increase cardiac
sympathetic activity in response to blood volume expansion (21). This demonstrates
that the PVN’s influence on BP and the CV system is mediated through hormones,
sympathetic neurons and interactions with the kidney. The stimulation of sympathetic
activity by PVN neurons in response to increased circulating angiotensin II (ANG II),
generated by the renin-angiotensin-aldosterone system (RAAS), is another example of
its interaction with the kidneys (11, 54).
Renin release from juxtaglomerular cells of the kidney primarily occurs in
response to hypovolemia and increased osmolarity but can also be produced by
sympathetic stimulation (11, 20, 38). Once released, the renin enzyme acts locally and
systemically in the blood to cleave angiotensinogen, which is constitutively secreted
by the liver into circulation, to form angiotensin I (38). Angiotensin I is then cleaved
by angiotensin-converting-enzyme (ACE), which is found in blood plasma, vascular
endothelial cells, the kidneys, the brain, the lungs and many other tissues (38, 40).
The product of ACE cleavage is the biologically active ANG II which has a multitude
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of effects on numerous organs and tissues. For instance, ANG II is a potent
vasoconstrictor, it acts on presynaptic receptors of sympathetic nerve terminals to
potentiate norepinephrine release, it decreases glomerular filtration rate and increases
reabsorption of sodium and water into the blood and it stimulates aldosterone release
from the adrenal cortex, thus completing the RAAS (38). It also acts on the
subfornical organ (a circumventricular organ of the brain) to stimulate PVN mediated
sympathoexcitation to the heart and kidneys (20, 40, 54). However, it is very
important to note that this classic, endocrine view of the RAAS has undergone
profound conceptual change due to the discovery of local, tissue-intrinsic reninangiotensin systems (RAS – note the distinct acronyms denoting local and circulatory
renin-angiotensin systems) and its importance in autocrine and paracrine signalling
which act independently of the circulating RAAS factors (32, 115).
Thus, both neural and humoral mechanisms interact with the ANS to modulate
autonomic activity and CV function. For example, the PVN and the RAAS influence
blood volume, vascular tone and BP; baroreceptors regulate BP and maintain it within
a set range by modulating cardiac function; ANG II produced by the RAAS can act
directly on peripheral sympathetic synapses and can modulate PVN activity; and the
PVN can directly modulate sympathetic outflow and influence the brainstem circuitry
that mediates the baroreflex (40). All of these systems are integrated through the ANS
and cooperate to maintain CV homeostasis.

1.5 Autonomic Dysfunction and Cardiovascular Dysregulation in T1DM
Dysfunction of the ANS is a common and serious complication of T1DM that
can result in dysregulation of all of the organ systems under its control (30). Known
as diabetic autonomic neuropathy (DAN), prevalence of this condition has been
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reported to vary widely, ranging from roughly 10-90% in diabetics depending on the
assessment criteria used (30, 149). The clinical manifestations of DAN are also
variable due to the systemic influence of the ANS and can include orthostatic
hypotension, tachycardia, hypertension, silent myocardial ischemia, gastroparesis,
xerostomia, decreased heart rate variability (HRV), anhidrosis and many others
symptoms (30, 33, 69, 95, 149). However, it should be noted that experimental forms
of diabetes do not always faithfully replicate the full spectrum of clinical
complications; in some cases, opposing outcomes have been observed, such as resting
bradycardia and hypotension (6, 47, 81). However, unlike the clinical population,
most of these studies do not use insulin therapy to manage hyperglycemia, which has
been shown to reverse those effects (47). DAN can also be a considerably deadly
complication of T1DM as it underlies diabetes-mediated CV dysfunction (85, 100).
Indeed, based on an analysis of the Pittsburgh Epidemiology of Diabetes
Complications Study, Orchard et al. (100) found that mortality increased fourfold in
patients with DAN.

Similarly, a meta-analysis by Maser et al. (85) found that

cardiovascular autonomic neuropathy (CAN), a subset of DAN, significantly
increased the relative risk of mortality by a factor of 3.45. Another form of mortality
in T1DM is the occurrence of sudden nocturnal death (100, 154). This so called “dead
in bed” syndrome is thought to be exacerbated by increased susceptibility to nocturnal
hypoglycemia resulting from abnormal pancreatic α-cell function and impaired
glucagon release (140, 154). However, even this impaired glucagon response is
thought to be mediated by autonomic dysfunction and furthermore, sudden death in
T1DM is more greatly attributed to cardiac arrhythmia than hypoglycemia; thus,
“dead in bed” syndrome is likely resultant of DAN (140, 154). DAN, therefore, has a
significant impact on the quality of life, morbidity and mortality of patients with
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T1DM; the most deadly consequences of which are mediated by loss of CV control
via CAN (30, 101, 149, 151).
As described previously, the etiology of general diabetic neuropathy and thus,
DAN, in T1DM is linked to chronic hyperglycemia (127, 155). Evidence of this was
reported by the Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) Study Research Group (98) who
observed that maintenance of near normoglycemia via intensive insulin therapy
reduced neurologic complications of T1DM and resulted in a 42% decrease in the risk
of any CV disease event, such as myocardial infarction, stroke or death. The
neuropathic effects of hyperglycemia that mediate DAN usually affect longer nerves
first and since the single longest ANS nerve, the vagus nerve, facilitates 75% of all
parasympathetic activity, a sympathovagal imbalance leading to sympathetic
overactivity is purported to be an early cause of CAN (30, 149, 151). Furthermore,
hyperglycemia can lead directly and indirectly to increased sympathetic outflow,
indicating peripheral and central mechanisms are behind ANS and CV dysfunction in
T1DM (108, 148). It is pertinent then to understand how the regulation of autonomic
activity and CV function are affected by T1DM.
Although there has been some evidence for increased RAAS activity in T1DM
and hyperglycemia, most of the literature has demonstrated that systemic components
of the RAAS, such as plasma renin, aldosterone and ANG II, are suppressed (13, 22,
73, 89). When considering this in the context of the physiological action of circulating
ANG II (vasoconstriction, volume expansion and sympathoexcitation), it should
follow that it is not involved in the increased BP and sympathetic tone observed in
T1DM; however, this is not the case (115, 148). More recent evidence implicates the
role of local, tissue-intrinsic RAS systems in the pathology of diabetes-related
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complications (109, 115). Hyperglycemia has been shown to increase local RAS
activity in numerous tissues and this process is being connected to the onset of many
downstream complications of T1DM; including, nephropathy, retinopathy and cardiac
myopathy (27, 34, 67, 110). This widespread deleterious effect of local RAS
overactivity in diabetes is likely interconnected to oxidative damage mediated by
locally produced ANG II (34, 115). Thus, RAS activation in diabetes is believed to
contribute to microvascular complications and has a probable role in the vascular
etiology of neuropathy (86, 109). Due to the presence of RAS in the brain and the
known ability of ANG II in the subfornical organ to elicit PVN-mediated increases in
sympathetic activity, there exists a plausible mechanism by which local RAS may be
driving increased sympathetic outflow in T1DM (11, 148).
The PVN of the hypothalamus is known to influence the basal level of
sympathetic outflow (60). In T1DM there are increases in both basal PVN activity and
sympathetic activity (35, 56). It has been demonstrated that the excitation of the PVN
by ANG II is enhanced in rats with streptozotocin (STZ)-induced diabetes; an
experimental form of T1DM produced by STZ-mediated destruction of β-cells (103).
This suggests that diabetes induced elevations of sympathetic outflow could be due to
increased levels of ANG II in the brain produced by local RAS system activation or
increased sensitivity to ANG II in the PVN (103). Another previously described
diabetes-related deficit that is also a mechanism contributing to central sympathetic
overactivity in T1DM is the loss of NOS activity and NO (138, 161). NO is a known
inhibitor of PVN activity that acts by increasing GABAergic input to the PVN (160).
Zheng et al. (161) found that STZ-diabetic rats had fewer neuronal NOS (nNOS)
positive cells and lower NO release in the PVN compared to controls. Thus, there is a
reduction of GABA inhibition on the PVN in T1DM that facilitates its overactivity
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and thereby, contributes to sympathetic

overactivity (114). Furthermore,

overstimulation of the PVN would also cause excitation of magnocellular neurons,
resulting in the release of vasopressin, which would contribute to increased BP via
direct vasoconstriction and volume expansion (70). However, the aberration of
sympathetic tone in diabetes is more directly influenced by the parvocellular neurons
of the PVN due to their association with the RVLM and IML; hence, PVN
dysfunction can dysregulate sympathetic outflow and CV parameters by modulating
neural control of HR, BP and the baroreflex (20, 60, 103).
The baroreflex itself is an important regulator of sympathetic and
parasympathetic outflow, BP, HR and TPR (84). Baroreflex dysfunction, in both
sensitivity and set point, is an established consequence of T1DM, with reductions in
sensitivity observed to occur as early as 5 days after STZ-diabetes induction (15, 23,
81). Thus, studies have investigated how each aspect of the baroreflex arc are
uniquely affected in T1DM; this arc consists of baroreceptors, baroreceptor afferents,
central regulators and sympathetic and parasympathetic efferents (74). Salgado et al.
(122) found that aortic baroreceptor neurons have reduced activity in STZ-diabetic
rats. Further, they determined that the aortic depressor nerves, the afferent nerves
between baroreceptor neurons and the brainstem, showed morphological signs of
axonal atrophy by measuring the G ratio; the ratio between axon diameter and whole
fiber diameter (122). Li et al. (72) observed that the excitability of aortic
baroreceptors, which mediates the set point of baroreceptor firing, was blunted in
STZ-diabetic rats and that later, this reduced excitability was due to up-regulated,
ANG II-NADPH oxidase derived, superoxide within the baroreceptor ganglion (73).
They also found that microinjection of an ANG II receptor antagonist into the nodose
ganglia restored aortic baroreceptor excitability, making the case for diabetes-induced
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local RAS activity being responsible for dysfunction of the afferent portion of the
baroreflex arc (73). Evidence for the dysfunction of central regulation of the
baroreflex was presented by Gu et al. (39) using OVE26 T1DM mice; a transgenic
model of T1DM that acquires β-cell damage through an overexpressed calmodulin
regulated by an insulin promoter. They found that these mice, compared to controls,
had a less prominent bradycardia response to aortic depressor nerve stimulation but
that the bradycardia response to vagal efferent stimulation was increased; suggesting a
central mechanism was responsible for the blunted response to baroreceptor
stimulation (39). Also, Chen et al. (16) documented a reduced firing rate in the NTS,
both basally and after phenylephrine injection, in STZ-induced diabetic rats compared
to controls. This decreased activity was implicated in their observation of decreased
baroreflex sensitivity (BRS) and could possibly indicate chronic disinhibition of the
RVLM; and therefore, increased sympathetic outflow (16). Of the two efferent arms
of the ANS, the PSNS appears to be the one primarily impaired in T1DM. Maeda et
al. (81) reported significant decreases in both basal PSNS tone and responsiveness to
hypertensive drugs in STZ-induced diabetic rats; but non-significant changes to
similar parameters in the SNS. Lund et al. (79) found that choline acetyltransferase
(ChAT, the enzyme that produces the chief neurotransmitter of the PSNS,
acetylcholine), had reduced activity in the hearts of diabetic rats as early as 4 weeks
post-STZ induction. After 8 weeks of diabetes, they measured a reduction in cardiac
ganglion size and number, prompting the conclusion that these PSNS deficits may
contribute to the impaired parasympathetic control of the heart, sympathetic
overactivity and baroreflex blunting that is common in T1DM (79).
A non-invasive functional measure capable of detecting such impaired
autonomic control of the heart in T1DM is the assessment of HRV (75). HRV can be
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measured by time domain analyses, measuring the changes in the standard deviation
between R-R intervals or by frequency domain analyses, using Fourier analysis to
disintegrate HR variance into underlying high and low frequencies (136). Regardless
of which method is chosen, HRV has been described as one of the earliest indicators
of autonomic dysfunction in T1DM (126, 162). A variable HR has been known to be
a characteristic of a healthy heart for roughly a century (37). In frequency domain
analysis, high frequency (HF) variation (0.15-.4Hz) is considered to be mediated by
parasympathetic activity, whereas low frequency (LF) variation (0.04-0.15Hz) is
considered to be entrained by the oscillation of baroreceptor firing; and so, it is
modulated by both parasympathetic and sympathetic activity (37, 136). As described
above, T1DM results in baroreflex dysfunction that is largely attributed to damage of
the PSNS (29). Since PSNS dysfunction occurs first, a reduction in HF variability is
usually the first sign of autonomic dysfunction (52). Thus, in general, a reduction in
HRV in T1DM is associated with the onset of autonomic dysfunction and more
specifically, the loss of parasympathetic tone and baroreflex dysfunction (37, 126,
157). Now used as a standard indicator in the diagnosis of cardiac autonomic
neuropathy, reduced HRV is associated with cardiac arrhythmias that can have mortal
consequences for diabetics and is therefore an important marker of autonomic
function in T1DM (151).

1.6 The

Effects

of

Exercise

on

Neuropathy,

Autonomic

Regulation

and

Cardiovascular Dysregulation in T1DM
Exercise training is a well-established and widely prescribed nonpharmacological therapy capable of ameliorating a wide breadth of diseases and their
complications (98, 105, 141). For example, exercise has been demonstrated to
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improve heart disease, pulmonary disease, muscle disease, bone disease, joint disease,
cancer, depression, asthma, obesity, hypertension, dyslipidemia, insulin resistance,
type 2 and type 1 diabetes (18, 105, 123, 128). Beyond just treating disease, exercise
is also associated with preventing disease risk factors and manifestation. It has been
shown to improve cognitive performance, increase longevity and has a strong
negative correlation with all-cause mortality (1, 64, 78). One of the underlying
principles likely facilitating the benefits of exercise is the concept of “hormesis”;
wherein low level stress or damage causes a disruption of homeostasis and results in
an adaptive overcompensation and increased fitness of a physiological system (14,
36). In the case of exercise, the acute induction of low-level oxidative stress and
inflammation results in an increase of endogenous antioxidant enzymes and antiinflammatory mediators (59, 132). Continuous exercise training results in the chronic
upregulation of antioxidants and anti-inflammatory agents which confers constitutive
resistance to other sources of pathogenic insult (132, 133). Another outcome of
exercise, which is especially important in diabetes, is increased insulin sensitivity and
glucose tolerance (43). Exercise training increases the amount and function of
proteins in the insulin signalling cascade, which facilitates the translocation of glucose
transporter 4 (GLUT4) into the skeletal muscle membrane (53). Furthermore, muscle
contraction can upregulate GLUT4 translocation to the plasma membrane via an
insulin-independent mechanism (118). In T1DM, hyperglycemia mediated ROS act to
decrease insulin sensitivity by impairing the insulin cascade and GLUT4 translocation
(44). Therefore, the antioxidant, anti-inflammatory and glucoregulatory effects of
exercise make it a potent therapy for T1DM and many of its complications (9, 36).
The influence of exercise on insulin sensitivity and glucose tolerance both
directly and indirectly affects nerve health. This is because neither nerves nor
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endoneurium express GLUT4 or utilize it to transport glucose; instead, they use
GLUT1 and GLUT3 which do not require insulin for translocation and are
constitutively active (82, 131). Thus, exercise-mediated sensitization to insulin does
not occur within neural tissue, yet through improving glucose tolerance in other
tissues, exercise reduces exogenous insulin requirements and neural hyperglycemic
insult in T1DM (105, 112, 158). This moderated hyperglycemia reduces the level of
AGEs, which are known to be major contributors to neuropathy through ROS
formation and inflammation in the neurovasculature (36, 41, 117). Furthermore,
exercise-induced insulin sensitivity and AGE reduction also means increased NO
production and bioavailability, resulting in enhanced function of endoneurial
capillaries and oxygen delivery to peripheral nerves (117, 135, 138). Exercise training
also increases endothelial Cu/Zn-superoxide dismutase (SOD) and mitochondrial MnSOD

antioxidant

enzymes

independently

of

hyperglycemic

status,

while

simultaneously decreasing inflammatory cytokines and increasing anti-inflammatory
mediators (51, 59, 93). Thus, exercise training is capable of ameliorating neuropathy
through the alleviation of both its metabolic and vascular etiologies by improving
glucose metabolism and upregulating antioxidant and anti-inflammatory mediators
(36, 112, 158). Indeed, exercise training has been shown to both, prevent diabetic
neuropathy from occurring and improve nerve function in individuals previously
diagnosed with diabetic neuropathy (9, 62).
Another mediator of T1DM complications that is influenced by exercise is the
local RAS (115, 121). RAS overactivity has been shown to be mediated by
hyperglycemia and is implicated in causing insulin resistance (45, 148). As previously
described, exercise can reduce hyperglycemia and so can decrease hyperglycemiamediated RAS stimulation. Furthermore, exercise results in the down-regulation of
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components of the RAS system, such as ACE, ANG II, ANG II type 1 receptor
(AT1), and NADPH oxidase (43, 57, 106, 121). Indeed, exercise has been shown to
decrease plasma ANGII and local RAS activity in cardiac muscle, blood vessels and
the brain (2, 121, 159). For example, Kar et al. (57) found that 3 weeks of treadmill
running decreased ACE mRNA in the NTS, RVLM, PVN and decreased sympathetic
outflow in rabbits with induced heart failure. Similarly, Pan et al. (102) found that
non-T1DM Sprague-Dawley rats had decreased AT1 and NADPH oxidase protein
expression and decreased superoxide production in the PVN following 3 to 4 weeks
of exercise training. As aforementioned, the PVN is activated in T1DM through
increased ANGII and decreased NO and this leads to sympathetic overactivity (103,
161). Thus, inhibiting RAS activity and ANGII production, while increasing NO
bioavailability, are likely mechanisms by which exercise reduces PVN mediated
sympathetic outflow (102, 117). This influence of exercise on RAS activity in the
PVN, NTS and RVLM makes it likely that exercise will also influence baroreflex
function in T1DM (55, 57, 102).
Since exercise can influence both vascular and neural function, both must be
taken into account when assessing the influence of exercise on BRS and baroreceptor
set point (65, 120). Indeed, both the neural structures involved in the baroreflex arc
and the carotid artery compliance can affect BRS and baroreceptor firing in diabetes
and exercise (65, 94, 120). Monahan et al. (94) found that both age-related and
exercise induced changes in the BRS corresponded to differences in carotid artery
compliance in healthy men. However, Komine et al. (65) determined that endurance
training increased BRS through alterations to the neural circuitry. In this vein, Miki et
al. (88) reported that exercise has been demonstrated to cause a shift in baroreflex
control of sympathetic nerve output to visceral organs. Further, Ruiz et al. (120)
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reported that diabetic neuropathy is a more significant determinant of BRS than
carotid artery elasticity in T2DM. Whether mediated by carotid artery compliance,
neural circuitry or a combination of both, exercise has been shown to increase BRS
after even a single bout of aerobic exercise in STZ-diabetic rats (55). Furthermore, the
benefits of aerobic exercise on baroreflex function have been shown to persist after 3
weeks of detraining subsequent to 10 weeks of moderate intensity training (50-70%
maximal running speed) in STZ-diabetic rats (96). Thus, exercise can be an effective
means to rescue or prevent baroreflex dysfunction and mitigate aberrations of CV
function in T1DM (42, 65, 102).
Since baroreflex function is directly linked to the neural control of HR,
fittingly, HRV is also influenced by exercise (119). In T1DM, there is generally a
reduction in HRV; an indication of autonomic dysfunction (17). However, in
individuals with T1DM there are inconsistent changes in HRV in response to
exercise. Chen et al. (17) reported that children with T1DM with moderate to high
physical activity did not differ in HRV compared to controls, whereas children with
low physical activity had reduced HRV, suggesting only higher intensity exercise
prevented a decline in HRV. On the other hand, Zoppini et al. (164) observed no
change in total HRV following twice-weekly exercise over 6 months but did find that
it increased HF power and lowered the LF/HF ratio, meaning there was a shift toward
more parasympathetic output in the sympathovagal balance. Howorka et al. (49)
tested HRV responses to 12 weeks of bicycle training in diabetic subjects who had
differing levels of cardiovascular autonomic neuropathy. They found that patients
without CAN had the greatest increases in HRV, patients with early CAN had lesser
increases in HRV and patients with severe CAN did not improve following training;
suggesting the level of neuropathy can dictate the outcomes of exercise (49).
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Therefore, the intensity of exercise and stage of disease both factor in to the ability of
exercise to modulate HRV in T1DM.
Some inconsistency in the effectiveness of exercise modulation of HRV is
reflected by the somewhat mixed outcomes for the influence of exercise on autonomic
function in T1DM. For example, De Angelis et al. (5) found that exercise training in
STZ-diabetic rats did not modify sympathetic tonus nor parasympathetic function. In
the same model, Wegner et al. (153) reported that training did not induce changes in
markers of parasympathetic innervation of the heart. However, vagal tonus and
function have been observed to improve after acute and prolonged training in the
STZ-diabetic model (96, 111). Indeed, the majority of literature supports the role of
exercise as an effective means to improve and maintain autonomic function in
diabetes (17, 150).

1.7 Summary
The pathogenesis of neuropathy in T1DM is a product of hyperglycemia-mediated
AGEs, oxidative stress, metabolic dysfunction, inflammation and microangiopathy
(41). Diabetic neuropathy affects peripheral and central aspects of the autonomic
nervous system, alters the homeostatic maintenance of the sympathovagal balance and
leads to a variety of systemic complications (30, 40). One of the most common and
serious complications of DAN is cardiovascular dysregulation (85). The local RAS,
PVN of the hypothalamus and baroreflex circuitry all interact to regulate autonomic
cardiovascular control (40, 41). In T1DM, hyperglycemia causes an increase in local
RAS, which in turn generates local ANGII mediated oxidative stress that can decrease
insulin sensitivity, blunt the excitability of baroreceptor neurons and increase PVN
activity (45, 72, 103, 148). This altered PVN activity interacts with the central
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mediators of the baroreflex and directly with preganglionic neurons to influence
sympathetic and parasympathetic outflow (8, 56). Thus, the baroreceptors, afferent
nerves, central neural structures and efferent nerves of the baroreflex arc are all
affected by T1DM (74). Together, dysfunction of these circuits underlie many of the
serious functional CV complications associated with DAN (40, 100). Exercise is not
only known to improve CV function directly but is also capable of improving ANS
regulation of CV control in diabetics (17, 105, 150). Through improving insulin
sensitivity and glucose metabolism, as well as the hormetic induction of antioxidant
and anti-inflammatory factors, exercise is capable of decreasing local RAS, reducing
PVN activity and improving the baroreflex and overall autonomic function in T1DM
via both molecular and physiological mechanisms (36, 43, 65, 102, 159). Therefore,
despite some inconsistencies between clinical and animal trials examining the
effectiveness of exercise in the improvement of autonomic control of CV function,
exercise remains an established, promising intervention for improving the prognosis
of those with T1DM.
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Figure 1.1. Protein glycation as the common cause of neuropathy; from Harati
2007 (41).

25

Figure 1.2. The baroreflex circuit; from Guyenet 2006 (40).
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CHAPTER 2
2.1 Introduction
One of the most common and serious complications of type 1 diabetes mellitus
(T1DM) is diabetic autonomic neuropathy (DAN) (20, 95). The prevalence of DAN
can range from roughly 10% in those recently diagnosed with T1DM, up to 90% in
patients who are awaiting pancreas transplantation (20, 43, 95). Due to the breadth of
the autonomic nervous system (ANS) throughout the body, DAN can influence the
dysfunction of virtually any organ system (95). The involvement of the ANS in the
homeostasis of so many systems is likely implicated in the four-fold increase in
mortality observed in T1DM patients with DAN (64). One of the most critical system
affected by DAN is the cardiovascular (CV) system (57). Cardiovascular autonomic
neuropathy (CAN) is a subset of DAN characterized by impaired autonomic control
of the CV system (46). CAN is consistently associated with increased mortality. For
instance, CAN has been reported to increase mortality of diabetics by a factor of 3.45
and further, symptomatic CAN 5 years after the onset of type 2 diabetes has been
shown to predict mortality 5 years later, even after adjusting for other cardiovascular
disease risk factors (48, 57, 97).
The etiology of DAN and thus, CAN, stems from both metabolic and vascular
pathologies that arise as consequences of sustained hyperglycemia (84, 100).
Hyperglycemia leads to the irreversible binding of glucose to proteins, forming what
are known as advanced glycation end-products (AGEs) (30). These AGEs exacerbate
the formation of reactive oxygen species (ROS) by inhibiting the function of
antioxidant enzymes and impair vascular dynamics by inhibiting nitric oxide synthase
(NOS) function, promoting inflammation and atherosclerosis of endoneurial
microvessels (30, 83, 89). This leads to further metabolic dysfunction, decreased
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nerve conduction and reduced oxygen delivery to nerve tissue and ultimately,
neuropathy (30, 81, 84).
When this neuropathy occurs in the ANS it leads to an imbalance between the
sympathetic (SNS) and parasympathetic (PSNS) nervous systems and dysregulates
their control of cardiac and vascular dynamics (20, 97). Often, this balance shifts
towards greater sympathetic activity in early T1DM as longer nerves are affected first
and the longest efferent ANS nerve, the vagus nerve, facilitates 75% of all
parasympathetic activity (20, 95). However, peripheral receptors, afferent nerves and
central regions regulating autonomic activity are also implicated in the imbalance of
the ANS during DAN (42, 50, 78). Together, the dysfunction of these ANS
components leads to the sympathetic overactivity, hypertension, tachycardia and
cardiac arrhythmias characteristic of

CAN in T1DM (21, 44, 46, 68, 80, 97).

However, it has been observed that as the duration of T1DM progresses, so does
neuropathy of the SNS, which can reduce sympathetic overactivity and its associated
symptoms (46, 80).
The most common methods for assessing CAN are heart rate variability
(HRV) analysis and baroreflex sensitivity (BRS) measurement (5, 46, 52). In T1DM,
it has been shown that all aspects of the baroreflex arc can be impaired (51). For
instance, both baroreceptor activity and excitability have been shown to be blunted
(50, 78); the aortic depressor nerves have been observed to undergo axonal atrophy
(78); central regions have been implicated as the limiting factors of BRS (9, 27); and
autonomic efferents, primarily of the PSNS, have been reported to have decreased
tone, reduced responsiveness and decreased neurochemical activity in the heart (54,
55). Each of these changes can act to reduce the sensitivity of the baroreflex
independently and in conjunction. However, reduced HRV is often the earliest
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symptom of CAN (80). Whether measured by time domain analysis or by frequency
domain analysis and whether in clinical or experimental T1DM, HRV is consistently
reported to be reduced in T1DM, with significant decreases observed as early as 10
days after diabetes induction in the experimental streptozotocin (STZ) model of
T1DM (34, 52, 79, 80, 102).
Exercise has been demonstrated to be an effective means of improving these
deficits of HRV and BRS in both clinical and experimental T1DM (11, 45, 61, 67).
Such improvements have been attributed to improved insulin sensitivity, increased
antioxidant and anti-inflammatory mediators and improved autonomic control of the
CV system (23, 32, 96). However, despite clinical and experimental forms of T1DM
demonstrating similar reductions of HRV and BRS in response to diabetes and
improvement with exercise, there are marked differences in the initial changes to
other CV parameters in their early stages (33). More specifically, in clinical T1DM,
increases in heart rate (HR) and blood pressure (BP) are commonly reported in early
DAN (12, 14, 46, 47, 80, 95, 96). In contrast, experimental, STZ-induced T1DM is
regularly associated with decreases in BP and HR beginning shortly after diabetes
induction (16, 19, 34, 79, 91). Due to these opposing initial changes in BP and HR,
exercise training is observed to effect contrasting outcomes on these CV parameters in
experimental and clinical T1DM; namely, it results in an increase in BP and HR in
experimental T1DM and a decrease in BP and HR in clinical T1DM (1, 31, 33, 53,
67). As a result, both the increase and decrease of those CV factors are concurrently
cited as exercise mediated improvements to CAN with little consideration of the fact
that the changes are reversed between these types of diabetes (33).
This may be due to a discrepancy between clinical and experimental T1DM in
the disease progression. The most common method of STZ-diabetes induction is a

43

single bolus injection of STZ typically ranging from 50-100mg/kg (18, 74, 104).
Aside from causing rapid pancreatic β-cell destruction and severe hyperglycemia,
high doses of STZ have been associated with bone loss, increased lipid peroxidation,
liver and kidney oxidative stress and even immunosuppression (41, 62, 63, 69).
However, increasingly, a multiple low-dose treatment of STZ is being demonstrated
to more closely represent the gradual pathogenesis of clinical T1DM and has even
been demonstrated to induce inflammation (74, 99). Indeed, Wei et al. (99) found that
5 consecutive days of STZ injection at 25mg/Kg resulted in the generation of
autoantibodies against insulin and islets of Langerhans and induced T cell infiltration
in the β-cells of primates. Thus, this model may more closely replicate clinical
parameters of the progression of DAN and CV dysfunction in T1DM by incorporating
an immune response and more gradually introducing cytotoxicity and hyperglycemia
(74, 96, 99).
Another important difference between experimental and clinical T1DM is the
common omission of insulin treatment in experimental diabetes. Indeed, of the
experimental studies listed above that showed reductions in HR and BP, not one
utilized insulin therapy and all animals presented severe hyperglycemia ranging from
roughly 17-25mM (16, 19, 34, 79). As the severity and duration of hyperglycemia
have been shown to influence the degree of diabetic neuropathy and with evidence
that intensive insulin therapy can reduce neurologic complications of T1DM, it has
been suggested that such acute and steep elevations of blood glucose levels in STZinduced diabetes are causing early-onset neuropathy to not only the PSNS but to the
SNS and the sinoatrial node as well; which is likely mediating the observed reduction
in BP and HR (2, 20, 30, 59, 64). Indeed, intensive insulin therapy has been shown to
restore BP and HR to control levels in STZ-diabetic rats (33, 35). Therefore, the
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disparity of insulin therapy in clinical and experimental diabetes can have a
significant impact on the progression of CAN and the CV dysfunction that is
observed. However, even in clinical T1DM, it is often the case that chronic, moderate
hyperglycemia is maintained as a result of difficulties in regulating blood glucose in
response to dynamic influences on glycemic control, such as food intake and exercise,
combined with the tendency to err on the side of hyperglycemia in order circumvent
the discomfort and danger associated with hypoglycemic episodes; which occur more
frequently with DAN due to the impairment of the glucagon response (15, 70, 86, 94).
Thus, whereas many diabetic complications and their modification by exercise
training are similar between clinical and experimental diabetes, important
inconsistencies exist that warrant resolution (2, 33). As such, the objectives of this
study are to mirror the moderate hyperglycemic state common to poorly controlled
human T1DM by employing a model of multiple low-dose STZ-induced diabetes in
combination with insulin therapy, while examining the capacity of high intensity
aerobic training to improve indices of CAN. Specifically, it is hypothesized that: a)
this model of T1DM will prevent the decline in HR and BP typical of other STZ
models, result in the hypertension and tachycardia typical of clinical T1DM and
induce reductions in HRV and BRS; and b) exercise training will improve or prevent
deficits in HRV and BRS.

45
2.2 Materials and Methods

Ethics approval
The protocols used in this investigation were approved by the Research Ethics Board of
the University of Western Ontario (London, Ontario, Canada) and conformed to the
guidelines of the Canadian Council on Animal Care (Appendix B.1).

Animals
Eight-week-old male Sprague-Dawley rats were obtained from Charles River
Laboratories Canada (Saint-Constant, Quebec). The rats were housed in pairs and maintained
on a 12-hour dark/light cycle at a constant temperature (20 ±1°C) and relative humidity
(50%). Rats were allowed access to standard rat chow and water ad libitum.

Experimental groups
Sixty-four rats were randomly assigned to one of four groups as follows: 1) Nondiabetic sedentary control (C; n=16), 2) control exercise (CX; n=16), 3) diabetic sedentary
control (D; n=16), 4) diabetic exercise (DX; n=16). A subset (n=8) of each group was used
for tests of autonomic cardiovascular control at the end of the experiment. However, the total
n used for testing varied based on animal availability at the time of the test.

Experimental procedures
Diabetes Induction

Upon arrival rats were acclimatized to the laboratory setting for 5 days. T1DM
was induced over 5 consecutive days by multiple intraperitoneal (IP) injections of
20mg/kg streptozotocin (STZ; Sigma-Aldrich) dissolved in a citrate buffer (0.1 M, pH
4.5). Diabetes was confirmed by blood glucose measurements greater than or equal
to18mM on two consecutive days. If necessary, subsequent 20mg/kg STZ injections
were administered until diabetes was confirmed (Appendix A1). Following the
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confirmation of diabetes, insulin pellets (1 pellet; 2U insulin/day; Linplant, Linshin
Canada, Inc., Toronto, Ontario, Canada) were implanted subcutaneously in the
abdominal region. Insulin pellet dosages were then monitored for 1 week and adjusted
(± 0.5 pellet) in order to obtain daily non-fasting blood glucose concentrations in the
moderate hyperglycemic range of 9-15mM (Appendix A2).

Exercise Protocol

Prior to the initiation of the exercise training program, rodents were familiarized
with the exercise equipment on two consecutive days. The familiarization consisted of
two 15 minute sessions of running at progressive treadmill speeds up to 30 meters per
minute. The exercise training program consisted of 1 hour of motor-driven treadmill
training per day at 27 m/min with a 6 degree incline, 5 days per week, for 10 weeks.
The exercise intensity was determined based on earlier research that investigated
oxygen uptake in rats at various treadmill speeds. The chosen intensity was found to
represent approximately 75-85% VO 2max (90) .

Experimental measures
Body Weight and Blood Glucose

Body weights and non-fasting blood glucose concentrations were obtained
weekly. Blood was obtained from the saphenous vein by venous puncture with a 30
gauge needle and measured via Freestyle Lite Blood Glucose Monitoring System
(Abbott Diabetes Care Inc., Mississauga, Ontario, Canada).

Insulin Dose
Insulin dose was determined by multiplying the total quantity of pellet implanted (0.5
pellet increments) by the amount of insulin secreted per pellet (2 units of insulin/day/pellet)
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divided by the body weight (Kg) of the rat. Insulin pellet dosages were then monitored and
adjusted throughout the course of the study in order to obtain daily non-fasting blood glucose
concentrations in the moderate hyperglycemic range of 9-15 mM (Appendix A2).

Intravenous Glucose Tolerance Test
Intravenous glucose tolerance tests (IVGTT) were performed on all animals
immediately prior to week 1 and at the end of week 10 of the exercise-training period. Rats
were fasted for approximately 8 to 12 hours prior to the assay and did not perform exercise on
the day of their IVGTT. A sterile-filtered dextrose solution (50% dextrose, 50% ddH 2 0) was
injected (1g/kg) into the lateral tail vein of the conscious rat. Following dextrose infusion,
blood glucose was measured at 5 minutes, 10 minutes and then at 10-minute intervals
thereafter until blood glucose levels plateaued (Appendix A3).

Non-invasive Blood Pressure
Non-invasive blood pressure (NIBP) recording was performed on all animals
immediately prior to week 1 and at the end of week 10 of the exercise-training period. NIBP
was recorded using the CODA non-invasive blood pressure system – tail cuff method (Kent
Scientific Corp., Torrington, Connecticut, USA). Rats were restrained in the provided
restraining tubes and tails were warmed with the included electrical heating pad. The
occlusion cuff was fitted at the base of the tail while the volume-pressure recording (VPR)
cuff was fitted 5cm distally. The occlusion pressure of the tail cuff was set to 180mmHg.
Data were recorded using the bundled CODA acquisition system software in 3 sets of 5
cycles. The first set consisted of 5 acclimation cycles, whereas sets 2 and 3 recorded 5 blood
pressure measurements each.

Surgery and Instrumentation
To achieve a surgical plane of anesthesia, rats were placed in an induction chamber
circulating 4% isoflurane (96% O 2 ). Once motor reflexes were undetectable, rats were
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transferred to a nosecone delivering 3% isoflurane (97% O 2 ) and placed on a hot water pad
(37°C). Immediately following transfer, rats were injected intraperitoneally (IP) with a
25mg/Kg “cocktail” of urethane (16mg/mL) and α-chloralose (100mg/mL). A total of 10mL
of urethane/α-chloralose was made, 5mL of which was diluted with 5mL of ddH 2 O and was
used as needed to maintain anesthesia throughout data collection. Isoflurane anesthesia
continued during instrumentation but was gradually removed near the end of surgery to gauge
the depth of urethane/α-chloralose mediated anesthesia.
Rats were cannulated with saline-infused polyethylene (PE90) catheters in the right
jugular vein and carotid artery and each catheter was attached to a three-way stopcock. The
jugular vein catheter was used for drug infusions and the carotid artery catheter was
connected in series with a pressure transducer (PX272, Edwards Life Sciences, Irvine,
California, USA) for arterial blood pressure measurements. Once cannulation was complete,
rats were transported to a new location for data acquisition, a process that required roughly
20-30 minutes. Heart rate (HR), systolic blood pressure (SBP) and mean arterial pressure
(MAP) were determined from the blood pressure pulse waveform and were collected while
the rats were under urethane/α-chloralose anesthesia in the supine position. The pressure
transducer was calibrated using a standard analog manometer. Data were obtained using a
PowerLab data acquisition system, digitized and recorded at1kHz using the bundled Lab
Chart 7 Pro software (ADInstruments, Colorado Springs, Colorado, USA).

Heart Rate Variability
Five minutes of resting, spontaneous BP and HR data were selected and analyzed for
HRV parameters prior to drug infusions using the HRV module included with the Lab Chart
software. Time domain analysis of the standard deviation between normal peak pulses of the
pressure pulse waveform (SDNN) was quantified as a measure of the total variability of the
HR. Frequency domain analysis of the high frequency (HF) band of the Fast Fourier
Transform (FFT) of the data was assessed as an index of parasympathetically mediated HRV.
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The ratio between low frequency (LF) and HF bands was measured to determine the
contribution of sympathetic activity to the sympatho-vagally mediated LF HRV.

Baroreflex Sensitivity
Baroreflex Sensitivity (BRS) was assessed using the modified Oxford technique (25,
37). The slope of the linear regression line (see Figure 2.1) was taken for the linear portion of
the systolic blood pressure-heart rate relationship (BPM mmHg-1) after rapid bolus injections
of phenylephrine (PE) and sodium nitroprusside (SNP) dissolved in ddH 2 O. For each drug,
the catheter was first filled with a 0.2mL volume to ensure the following dosage was accurate.
After a stable baseline was obtained, a bolus injection of SNP (60ug/Kg, 110ug/mL) was
rapidly infused (~5s) and the reflex SNS mediated tachycardia response was measured. The
analysis began at the onset of SBP decrease after SNP infusion and ended when SBP reached
its nadir. This was followed by a saline flush to washout any remaining SNP in the catheter.
This same procedure was then followed using PE (12ug/Kg, 10ug/mL) to measure PSNS
mediated reflex bradycardia, except that analysis began at the onset of SBP increase and
ended when SBP reached its zenith (See Table 1). Exclusions of data points in the threshold
and saturation regions of the sigmoid relationship were done manually in order to determine
linear gain. Responses to PE and SNP were plotted separately and only regression lines
(slopes) with correlation coefficients (r) ≥ 0.70 and p<0.05 were accepted (76, 85).

Vascular Sympathetic Tone
To measure the sympathetic tone of the peripheral vasculature, a rapid bolus injection
of the α-adrenergic receptor blocker, prazosin (85ug/Kg, 500ug/mL), was infused at the end
of the baroreflex testing and the change in MAP was assessed. Following this protocol,
animals were euthanized via exsanguination while still under urethane/α-chloralose
anesthesia.
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Data Analysis
Body weight, blood glucose concentrations, NIBP and IVGTT data were compared
using a two-way repeated measures analysis of variance (ANOVA) test, where the two factors
were time (week) and specific treatment group (C, CX, D, DX). When significance was
found, pairwise comparisons were made using the Fisher LSD post-hoc test. Endpoint
measures were compared by one-way ANOVA between treatment groups. When significance
was found, pairwise comparisons were made using the Fisher LSD post-hoc test. If initial
statistical tests indicated significance, secondary analysis was performed using a two-way
ANOVA to determine the main effects of and interaction between diabetes and exercise. If a
significant interaction was found, pairwise comparisons were made using the Fisher LSD
post-hoc test.
The insulin dosages were compared using a one-tailed t-test. In the event that both the
normality and equal variance assumptions were not met and significantly reduced the power
of the parametric one-way ANOVA, a non-parametric Kruskal-Wallis one-way ANOVA on
ranks was used and pairwise comparisons were made with a Dunn’s post-hoc test.
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Figure 2.1. Example of a typical regression line used to calculate the slope of the systolic
blood pressure-heart rate response to SNP for a single rat.

52

C

CX

D

DX

SBP

HR

SBP

HR

SBP

HR

SBP

HR

160.07

288.17

166.02

297.27

150.07

311.11

171.51

268.72

116.73

357.83

123.17

340.32

107.20

354.66

111.48

333.15

84.45

407.00

87.438

379.50

75.96

398.97

88.58

360.87

Zenith

Baseline

Nadir

Table 2.1. Coincident average systolic blood pressure (SBP, mmHg) and heart rate (HR,
BPM) at the baseline, zenith post-PE infusion and nadir post-SNP infusion. C, sedentary
control, n=7; CX, control exercise, n=6; D, sedentary diabetic, n=8; DX, diabetic exercise,
n=10.
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2.3 Results
Body Weight
All groups (C, n=16; CX, n=16; D, n=15; DX, n=12) significantly gained
weight over the course of the study (p<0.05). From Week 0 to Week 10, group C was
significantly different from all other groups (p<0.05). From Week 1 to Week 10,
group CX had significantly lower weight than C and significantly greater weight than
D and DX (p<0.05), with the exception of group D at week 4. From Week 4 to Week
10, with the exception of Week 6, group D had a significantly greater weight than DX
(p<0.05). Overall, rats in the diabetic conditions were significantly lower weight than
those in the non-diabetic conditions (p<0.001) and exercise conditions had
significantly lower weight than their sedentary counterparts (p<0.001). However,
there was not an interaction between diabetes and exercise on body weight (p=0.528)
(Figure 2.1).

Blood Glucose
The C (n=16) and CX (n=15) groups did not change nor significantly differ in
blood glucose throughout the study. The blood glucose of D (n=15) and DX (n=13)
increased significantly following STZ treatment (p<0.05) and remained significantly
elevated compared to C and CX throughout the study (p<0.05). Groups D and DX
were significantly different from week 2 to week 6 and at week 9 (p<0.05). Rats in
the diabetic conditions had significantly greater blood glucose concentrations than
those in the non-diabetic conditions (p<0.001). However, there was not a significant
interaction between diabetes and exercise on blood glucose (p=0.27) (Figure 2.2).
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Intravenous Glucose Tolerance Test
The glucose clearance rate (K G ) of D (n=16) and DX (n=8) decreased from
Week 1 to Week 10 (p<0.05) whereas the K G of CX (n=15) increased (p<0.05). Both
diabetic groups (D, DX) were significantly different from both control groups (C,
n=16; CX) at Week 10 (p<0.05). Indeed, there was a significantly lower K G for rats in
the diabetic conditions than for those in the non-diabetic conditions at Week 10
(p<0.05). However, there was not a significant interaction between diabetes and
exercise (p=0.906) (Figure 2.3).

Insulin Dosages
The amount of insulin supplementation that DX (n=18) received was
significantly less than D (n=16) received at Week 10 (p<0.001) (Figure 2.4).

Non-Invasive Blood Pressure
At week 1, the diabetic groups (D, =14; DX, n=11) had significantly higher
BP than the control groups (C, n=15; CX, n=16) (p<0.05). All groups (C, CX, D, DX)
increased in BP from week 1 to week 10 (p<0.05). At week 10, CX, D and DX had
significantly greater BP than C (p<0.05). At week 1 there was significantly higher BP
in rats in the diabetic conditions in comparison to those in the non-diabetic conditions
(p<0.05), however, there was not a significant interaction between diabetes and
exercise (p=0.076). Within non-diabetic groups at week 10, there was a significantly
higher BP in the exercise than sedentary conditions (p<0.05). Within sedentary
groups, there was significantly greater BP in the diabetic than non-diabetic conditions
at week 10 (p<0.05). Indeed, there was a significant interaction between diabetes and
exercise on BP at week 10 (p<0.05) (Figure 2.5).
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Heart Rate Variability and Heart Rate Variability
Resting heart rate (BPM) under anesthesia was not significantly different
between any groups (C, n=7; CX, n=7; D, n=8; DX, n=11) at week 10 (p=0.122)
(Figure 2.6). Total HRV, as measured by the standard deviation of the normal pulse
wave peaks (SDNN), was not significantly different between any groups (C, n=5; CX,
n=7; D, n=8; DX, n=8) at Week 10 (p=0.369) (Figure 2.7). The parasympathetic, high
frequency (HF) contribution to HRV had a significantly greater power for CX (n=7)
and DX (n=8) in comparison to D (n=8) at Week 10 (p<0.05). Further, there was
significantly greater HF HRV in exercise than sedentary conditions (p<0.05).
However, there was not a significant interaction between diabetes and exercise on HF
HRV (p=0.281) (Figure 2.8). The low frequency to high frequency (LF/HF) ratio, an
index of sympathetically mediated HRV, was significantly greater in the D (n=7)
group compared to all other groups (C, n=6; CX, n=6; DX, n=7) (p<0.05). The LF/HF
ratio was significantly greater in the diabetic than non-diabetic conditions and in the
sedentary than exercise conditions (p<0.05), however, there was not a significant
interaction between diabetes and exercise (p=0.068) (Figure 2.9).

Vascular Sympathetic Tone
The decrease in MAP in response to prazosin infusion was significantly
greater in the D (n=5) group compared to all other groups (C, n=8; CX, n=7; DX,
n=7) (p<0.05). Within the diabetic groups (D, DX), there was a significantly greater
decrease in MAP in the sedentary condition compared to the exercise condition
(p<0.05). There was a significant interaction between diabetes and exercise (p<0.05).
Within the sedentary groups (C, D), there was a significantly greater decrease in MAP
in the diabetic than non-diabetic condition (p<0.05) (Figure 2.10).
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Baroreflex Sensitivity
The slope of the tachycardia response to sodium nitroprusside infusion was
not significantly different between any groups (C, n=7; CX, n=6; D, n=6; DX, n=10)
(p=0.86) (Figure 2.11). The slope of the bradycardia response to phenylephrine was
significantly greater in the C (n=7) and DX (n=10) groups compared to the D (n=7)
group (p<0.05) but not CX (n=5). Within diabetic groups, there was a significantly
greater bradycardia response in the exercise than sedentary group (p<0.05). There was
a significant interaction between diabetes and exercise on the slope of the bradycardia
response (p<0.05) (Figure 2.12).
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Figure 2.2. Weekly body weights. Data are mean ± SE. C, sedentary control (n=16); CX,
control exercise (n=16); D, sedentary diabetic (n=15); DX, diabetic exercise (n=12). * =
significantly different from C (p<0.05). # = significantly different from CX (p<0.05). Ω =
significantly different from D (p<0.05). There is a statistically significant difference between
diabetic and non-diabetic conditions (p<0.001). There is a statistically significant difference
between exercise and sedentary conditions (p<0.05).
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Figure 2.3. Weekly blood glucose concentrations. Data are mean ± SE. C, sedentary control
(n=16); CX, control exercise (n=15); D, sedentary diabetic (n=15); DX, diabetic exercise
(n=13). * = significantly different from C (p<0.05). # = significantly different from CX
(p<0.05). There is a significant difference between diabetic and non-diabetic conditions
(p<0.001).
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Figure 2.4. IVGTT glucose clearance (KG) values at week 1 and week 10. Data are mean
± SE. C, sedentary control (n=16); CX, control exercise (n=15); D, sedentary diabetic
(n=16); DX, diabetic exercise (n=8). * = significantly different from C (p<0.05). # =
significantly different from CX (p<0.05). $ = significantly different from Week 1
(p<0.05). There is a statistically significant difference between diabetic and non-diabetic
conditions at week 10 (p<0.001).
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Figure 2.5. Insulin dosages at Week 10. Data are mean ± SE. D, sedentary diabetic
(n=16); DX, diabetic exercise (n=18). Ω = significantly different from D (p<0.001).
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Figure 2.6. NIBP values at week 1 and week 10. Data are mean ± SE. C, sedentary
control (n=15); CX, control exercise (n=16); D, sedentary diabetic (n=14); DX, diabetic
exercise (n=11). * = significantly different from C (p<0.05). # = significantly different
from CX (p<0.05). $ = significantly different from Week 1 (p<0.05). There is a
statistically significant interaction between diabetes and exercise at week 10 (p<0.05).
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Figure 2.7. Heart Rate (beats per minute) at Week 10. Data are mean ± SE. C, sedentary
control (n=7); CX, control exercise (n=7); D, sedentary diabetic (n=8); DX, diabetic
exercise (n=11). There is not a statistically significant difference between groups (p=0.122).
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Figure 2.8. Total HRV (SDNN) at Week 10. Data are mean ± SE. C, sedentary control
(n=5); CX, control exercise (n=7); D, sedentary diabetic (n=8); DX, diabetic exercise
(n=8). There is not a statistically significant difference between groups (p=0.369).
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Figure 2.9. High Frequency (parasympathetic) HRV component at Week 10. Data are mean
± SE. C, sedentary control (n=6); CX, control exercise (n=7); D, sedentary diabetic (n=8);
DX, diabetic exercise (n=8). Ω = significantly different from D (p<0.05). There was a
statistically significant difference between exercise and sedentary conditions (p<0.05).
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Figure 2.10. Low frequency to high frequency ratio (sympathetic) HRV component at Week
10. Data are mean ± SE. C, sedentary control (n=6); CX, control exercise (n=6); D,
sedentary diabetic (n=7); DX, diabetic exercise (n=7). * = significantly different from C
(p<0.05). # = significantly different from CX (p<0.05). @ = significantly different from DX
(p<0.05). There was a statistically significant difference between diabetic and non-diabetic
and exercise and sedentary conditions (p<0.05).
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Figure 2.11. Vascular sympathetic tone at week 10. This was determined by measuring the
percent change in MAP after prazosin treatment at Week 10. Data are mean ± SE. C,
sedentary control (n=8); CX, control exercise (n=7); D, sedentary diabetic (n=5); DX,
diabetic exercise (n=7). * = significantly different from C (p<0.05). # = significantly
different from CX (p<0.05). @ = significantly different from DX (p<0.05). There was a
statistically significant interaction between diabetes and exercise (p<0.05).
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Figure 2.12. Tachycardia baroreflex response sensitivity to sodium nitroprusside
at Week 10. Data are mean ± SE. C, sedentary control (n=7); CX, control
exercise (n=6); D, sedentary diabetic (n=6); DX, diabetic exercise (n=10). There
is not a statistically significant difference between groups (p=0.86).
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Figure 2.13. Bradycardia baroreflex response to phenylephrine at Week 10. Data
are mean ± SE. C, sedentary control (n=7); CX, control exercise (n=5); D, sedentary
diabetic (n=7); DX, diabetic exercise (n=10). Ω = significantly different from D
(p<0.05). There was a statistically significant interaction between diabetes and
exercise (p<0.05).
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2.4 Discussion
This study demonstrated that a multiple low-dose STZ model with moderate
hyperglycemia, maintained using insulin therapy, produced deficits in cardiovascular
autonomic function without inducing the resting bradycardia or hypotension typical of
other STZ models. Furthermore, this study showed that exercise training can prevent
the alteration of cardiovascular autonomic function caused by diabetes in this model.
Although time domain analysis of total HRV, as measured by the SDNN, did
not demonstrate differences between groups, frequency domain analysis of the
distinct contributions of the autonomic branches to HRV did reveal significant
differences. For instance, there was a significant difference in the HF power between
the D group and both exercise groups. Furthermore, the LF/HF ratio was significantly
higher in the D group compared to all other groups. Since the HF power corresponds
to the level of vagally-mediated (parasympathetic) HRV and the LF/HF ratio is a
measure of sympathovagal balance, these results indicate that there was significantly
lower parasympathetically-mediated HRV in the D group compared to the exercise
groups as well as an overall shift toward greater sympathetic activity in the
sympathovagal balance of the D group (75, 103). Thus, exercise training prevented
the dysregulation of the sympathovagal balance caused by diabetes. These findings
are similar to those of other experiments of both clinical and experimental diabetes. A
study by Zoppini et al. (103) demonstrated an increase in HF power and a decrease in
the LF/HF ratio but no change in total HRV, after 6 months of exercise in T2DM
patients. Mostarda et al. (61) found that STZ-induced diabetes reduced the HF
component of HRV which was improved by exercise. Also comparable to the present
study, they found that the vagal tonus of the control exercised rats did not differ from
sedentary controls (61). Chen et al. (11) reported that children with type 1 diabetes
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who performed high physical activity did not differ from controls in HRV; however,
they did find that children with type 1 diabetes who had low physical activity had
significantly reduced HRV compared to both active T1DM and control children.
Indeed, most studies report that diabetes decreases HRV even from control levels, yet
it is important to note that the timing of HRV decline is variable (2). Schaan et al. (79)
measured HRV at 5-7, 14, 30, 45 and 90 days post-STZ-induction of diabetes in rats
and found that there were no significant differences from control in HRV until the 30
or 45 day time points. Moreover, in this STZ model no insulin therapy was used,
which could indicate that significant decreases in HRV in the present study would
have taken even longer due to the reduced hyperglycemic insult. Indeed, the authors
reported that there was a negative correlation between plasma glucose levels and
reductions in HRV (79); an observation also noted by Chen et al. (10) in a study of
children with T1DM, in which they found that glycemic control had a greater negative
correlation with HRV than did disease duration. However, regardless of severity or
duration of hyperglycemia, it has been demonstrated that exercise is an effective
means to improve HRV as long as pre-existing CAN is not too severe (36, 75).
In fact, the current study provides evidence that the ability of exercise to
ameliorate cardiovascular autonomic dysfunction may be independent from its ability
to reduce blood glucose, which contradicts such an inference suggested by previous
studies (13, 87, 98). The IVGTT performed at the end of the 10 week exercise period
demonstrated an increased glucose clearance (K G ) in the CX group compared to week
1 of training, which indicates there was an increase in glucose tolerance in the
exercise control group. In both diabetic groups there was a decrease in K G to nearly
the same level that was significantly different from their week 1 values and the week
10 values of the C and CX groups. While this would normally indicate that both of the
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diabetic groups had equally impaired glucose tolerance, it was also the case that the
DX group received approximately half of the dosage of exogenous insulin than the D
group received. If this entails that the area under the curve for insulin over a given
time during IVGTT would have been greater in the diabetic group, then with the K G
being equal, this would indicate there was a greater insulin sensitivity in the diabetic
exercise group (29, 92). Together, these IVGTT results indicate improved glucose
metabolism and insulin sensitivity as a result of exercise training (87). However, since
the BG concentration in this study was held in a relatively constant range, any
exercise-induced improvements of CV function that resulted from improved glucose
metabolism would not have been mediated through an insulin sensitivity-induced
reduction in systemic blood glucose but could still be the result of tissue-specific
improvements in glucose utilization (6, 66). This should be borne in mind when
considering the effects of diabetes and exercise on BRS.
The sensitivity or “gain” of baroreflex-mediated tachycardia and bradycardia
were examined in this study by measuring the slope of the regression line of the
ΔHR/ΔSBP in response to the vasodilator SNP and the vasoconstrictor PE,
respectively. The slope of the tachycardia response was not significantly different
between any of the groups. The slope of the bradycardia response was not
significantly different from C in either exercise group; nor was there a significant
difference between the exercise groups. However, the slope of the bradycardia
response in the D group was significantly reduced compared to the C and DX groups.
The tachycardia elicited by SNP is mediated by baroreflex-induced disinhibition of
the RVLM, resulting in sympathoexcitation (28, 72). Thus, neither diabetes nor
exercise affected the function of the sympathetic arm of the baroreflex. Conversely,
the bradycardia induced by PE is mediated by baroreflex-induced inhibition of the
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RVLM, resulting in depressed sympathetic activity and increased parasympathetic
activity (28, 72). Therefore, diabetes reduced the function of the parasympathetic arm
of the baroreflex, a decline which was prevented by exercise. These results are
directly in line with a study by Jorge et al. (40) that investigated BRS after 30 days of
STZ-diabetes, with and without aerobic exercise during the final 5 days. They found
that neither diabetes nor exercise had any effect on the tachycardia reflex to SNP.
Further, they found that control exercised rats did not differ from the control group
before or after exercise training in either response. However, similar to the current
study, they found that diabetes decreased the bradycardia response to PE and that this
decrease was ameliorated by exercise (40). This indicates that the acute effect of
exercise in a more severe, yet shorter duration, model were similar to the outcomes of
the model employed in this experiment, giving credence to the postulation that the
multiple low-dose STZ, insulin supplementation approach reduces the speed of
neuropathic progression. However, it should be noted that Maeda et al. (55) observed
a decreased tachycardia response and unchanged bradycardia response after only 5
days post-STZ treatment. This suggested that in the very short-term, there may be
some neural toxicity of STZ directly on the SNS (24, 82).
An explanation of why short-term exercise in the study by Jorge et al. (40)
appears to have been as effective as endurance training in the current study may be
explained by the findings of Bernardi et al. (3), who elucidated the importance of
tissue oxygenation in T1DM. They demonstrated that blunted parasympathetic BRS
in T1DM patients was improved by both oxygen supplementation and deep breathing
to the same degree, which implicated the increased respiration and oxygen delivery
resultant of exercise could have been mediating increases in BRS (3). This led the
authors to suggest hypoxia in T1DM functionally restrains parasympathetic activity
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(3). Most of the studies discussed thus far, including this current experiment, are all in
line with the observation that parasympathetic dysfunction precedes sympathetic
dysfunction (38). However, reduced BRS can be attributed to defects in the
baroreceptors, baroreceptor afferent nerves, CNS structures or efferent fibres of the
baroreflex circuit (40, 51, 78). The observation in the present study that the
tachycardia response of the baroreflex was unimpaired by diabetes, while the
bradycardia response was, suggests that the afferent arm and central regulators of the
baroreflex were not dysfunctioning and that the observed decrement of baroreflex
bradycardia was due to efferent parasympathetic neuropathy (16, 78). Since the
maintenance of the tachycardia response to SNP indicates the functionality of the
baroreceptors in response to stretch was unhindered, it can also be inferred that
arterial stiffening was not a likely cause for the decreased bradycardia response (77).
It has been reported that arterial stiffening results in reduced arterial compliance,
which limits the magnitude of arterial stretch and thereby, the magnitude of the
baroreceptor firing (58). In fact, arterial stiffness has even been associated with
decreased HRV in type 1 diabetics (39). However, Ruiz et al. (77) reported that
neuropathy is a greater determinant of BRS than carotid artery elasticity in diabetes.
Further, Komine et al. (45) demonstrated the effects of exercise on BRS are mediated
through neural alterations, as opposed to changes in vessel wall compliance of the
carotid artery. Thus, the alteration in BRS of the bradycardia response in this study
was most likely due to the dysfunction of parasympathetic efferents, which was
prevented via exercise. This is corroborated by the VST observed in this study, which
was measured through the changes in MAP in response to prazosin treatment.
Prazosin injection resulted in a decrease in MAP in all groups. This decrease
in MAP, relative to baseline, was not significantly different between the C, CX and
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DX groups. Conversely, the drop in MAP from baseline in the D group was
significant compared to all other groups; the reduction being approximately twice as
large. Prazosin is an α1-adrenergic receptor antagonist that blocks the sympathetic
contribution to peripheral resistance at the level of the vascular smooth muscle (56,
71). Thus, a larger reduction in blood pressure in response to prazosin treatment
indicates a greater sympathetic tone in the maintenance of the baseline MAP (17, 73).
Therefore, the significantly greater decrease in the MAP of the D group in this study
indicates that diabetes resulted in a significant elevation of vascular sympathetic tone,
which was prevented by exercise training. Martinez-Nieves and Dunbar (56) reported
a similar finding that male diabetic rats had a greater decrease in MAP after a bolus
injection of prazosin compared to their control cohorts. They postulated that an
elevated prazosin response could be the result of increased α1-adrenergic receptor
sensitivity (56). However, the finding that treatment with PE, an α1-adrenergic
receptor agonist, did not have a greater impact in the diabetic group makes this an
unlikely explanation in this experiment (26). The result of prazosin treatment is in
concordance with both the HRV and BRS results in this study. HRV demonstrated a
similar shift toward sympathetic activity in the sympathovagal balance, as determined
by the LF/HF ratio. The BRS tests demonstrated a significant reduction in
parasympathetic modulation of the HR. In conjunction, these findings point toward a
diabetes-induced reduction in parasympathetic function, the consequent loss of PSNSmediated sympathetic inhibition and resultant sympathetic overactivity (95, 97). This
may explain the outcome of the NIBP measurement in this study.
The NIBP measurement of MAP in conscious rats showed a significant
increase in blood pressure at week 10 compared to week 1in all groups. At week 1,
the D and DX groups both had higher BP than the C and CX groups. At week 10, D,
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DX and CX all had similarly elevated blood pressures compared to C. The elevation
of BP in the diabetic groups at week 1 was likely resultant of their recent, acute
elevation in BG in response to STZ treatment, as acute elevations in BG have been
shown to increase BP in both normal and type 1 diabetic individuals, as well as
animals (4, 8, 22, 49). It is also possible that BP was elevated due to the osmotic
pressure caused by hyperglycemia; however, pre-treatment with the free radical
scavenger, glutathione, has been shown to prevent any acute hemodynamic changes
associated with hyperglycemia, suggesting its effects are more likely mediated by the
impairment of endothelial-derived relaxing factors, such as NO (22, 65). Also, stress
could have played a role in elevating the BPs of the diabetic groups at week 1.
Restraint alone has been observed to dramatically increase heat shock protein
expression in both the adrenal cortex and the vasculature (93). In fact, the stress of
training is probably why both exercise groups had BP values similar to the D group at
week 10. Moraska et al. (60) showed that 8 weeks of forced treadmill training caused
adrenal

hypertrophy,

decreased

corticosterone-binding

globulin,

suppressed

lymphocyte proliferation and other factors indicative of chronic stress. Likewise,
Brown et al. (7) reported elevated heat shock proteins, serum corticosterone and
decreased spleen weights after up to 10 days of treadmill training. Forced treadmill
exercise has also been demonstrated to mediate increases in BP and HR that exceed
the values of voluntary wheel running rats, which is indicative of a stress response
(60, 101). This is particularly relevant in the present study as the NIBP measurements
were taken during the week. Therefore, both the chronic stress of long-term training
and acute effects of forced training could have contributed to elevated BP in the
exercise groups. The D group, however, demonstrated increased BP without exposure
to acute or chronic training stress, suggesting their BP values were most likely the

76

result of chronic diabetes. As a result of the previous findings that indicated
sympathetic overactivity in the D group and the strong association between
sympathetic tone and BP, it is plausible that the observed hypertension is driven by
sympathetic overactivity in this model (73). However, urine albumin excretion was
not measured in this study, so it is not possible to rule out that diabetic nephropathy
contributed to the increased BP (88). Unfortunately, HR extrapolations from the NIBP
recordings were sporadic and deemed unreliable. However, while at rest under
urethane/α-chloralose anesthesia, there was no significant difference between any of
the groups in HR. Although it is unknown if non-invasive recording would have
demonstrated diabetes-induced tachycardia, this observation still demonstrates that
the commonly reported decrease in HR in STZ diabetes was prevented in the present
model (91).

2.5 Conclusion
Cardiovascular autonomic neuropathy is a common form of autonomic
dysfunction in T1DM that is highly associated with mortality (80). HRV and BRS are
common indices of CAN that have been observed to improve with exercise training,
highlighting why exercise is such an important nonpharmcological intervention in the
prevention of T1DM complications. However, experimental models of T1DM often
demonstrate fundamental differences from clinical T1DM in the nature and
progression of alterations to CV parameters in response to diabetes and exercise (33,
51). The objective of this study was to explore the potential of a multiple low-dose
STZ model of T1DM, paired with insulin therapy to maintain moderate
hyperglycemia, as a means to more closely represent the conditions of human T1DM.
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In this study it was found that the only measures that differed from C in the
CX group were the IVGTT and NIBP. Thus, training did result in metabolic
improvements, as indicated by increased glucose tolerance; however, exercise did not
appear to elicit any advantages in HRV, BRS or BP over the non-diabetic sedentary
state. This suggests that the chronic stress of forced treadmill training may have
prevented many of the benefits normally conferred by exercise to the CX group (7,
60, 101). In the D group, a blunted baroreflex bradycardia response, a shift in LF/HF
toward sympathetic activity and a significant drop in BP in response to prazosin
compared to C indicated diabetes-induced parasympathetic withdrawal and
sympathetic overactivity (28, 75, 103). This was supported by the significantly higher
NIBP compared to C. Similarly to CX, the only differences between DX and C in this
study were in IVGTT and NIBP. However, unlike CX, this implies that exercise
training resulted in significant adaptations. Indeed, exercise training in the DX group
was able to prevent many of the defects listed above that occurred in the D group as a
result of diabetes. Specifically, exercise prevented the sympathovagal imbalance in
the modulation of HRV, prevented the overactivity of the vascular sympathetic tone
and maintained the sensitivity of the parasympathetically-mediated baroreflex
bradycardia. Therefore, the present study demonstrated that STZ models of T1DM
can be augmented to more accurately reflect clinical T1DM by implementing
progressive induction and insulin treatment. Further, this study reinforces the
importance and effectiveness of exercise as a means to prevent the progression of
cardiovascular autonomic neuropathy.
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APPENDIX A
A1. Streptozotocin Induction Protocol (Rat)
REVISION DATE: JUNE 13, 2012
PURPOSE:
To induce Type I diabetes in rats
MATERIALS:
Gloves
Lab Coat
Streptozotocin (STZ)
5X Stock Citric Acid/Citrate Buffer
Anhydrous Citric Acid
Sodium Citrate Dihydrate
MilliQ Deionized Water
13M HCl
3 Falcon Tube
Sterile Filter
EQUIPMENT:
Biological Safety Cabinet
Weigh Scale
pH Meter
PROCEDURE:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid
Monohydrate
ii. 23.8g Sodium Citrate Dihydrate (Sigma)
Mix into iii. 175mL of MilliQ water
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH)
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml
mark (pH will move slightly). If satisfied with the pH, adjust volume in a 250 ml
graduated cylinder and filter in a 0.2µm filter.
3. Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection
**NOTE Animals should be pre-weighed prior to making up STZ to ensure
accurate amounts of STZ to be prepared.
1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL
of distilled water filtered through a 0.2µm syringe filter. Check the pH. This
gives you a working concentration of 153 mM
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2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HCl to the buffer, checking pH in between until desired pH is
reached.
3. Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm
syringe filter as before). If pH is below 4.5, restart.
4. Weigh out an appropriate amount of STZ for the number of animals (see
calculations below) that will be injected in a 15 minute time frame.

Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g
(avg. weight of rats to be injected), you will require a minimum of 40mg.
20mg/kg X 0.2kg = 4mg per animal
The amount of STZ weighed out should be more than the minimum as some
solution will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total
(0.048g)
5. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume).
Shake to dissolve powder (approx. 1min). Sterile filter using a 0.2µm syringe
filter.
Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution
4mg ÷ 16mg/mL solution = 0.25mL
6. STZ is time dependent and must be used within 15 minutes
Injecting and Follow-Up of the Animals
1. Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of
20mg/mL (in this example, 0.25mL). Do not use anymore STZ solution more
than 15 minutes after it has been dissolved in the sodium citrate buffer.
2. Dispose of any container having come into contact with the STZ (in either powder
or dissolved form) into a biohazardous waste receptacle. Dispose of needles into a
sharps container.
3. Return injected rats to their cage. Record the date of STZ injection and add a
biohazard label to the cage (leave biohazard label on cage for at least 3 days
following the last injection).
4. Repeat this procedure the following day.
5. Check blood glucose daily. Diabetes is achieved with two non-fasting blood
glucose readings of >18 mmol Diabetes should be achieved after 5-8 injections
(i.p. 20mg/kg).
Reference:
Low dose STZ induction protocol. Animal Models of Diabetic Complications
Consortium AMDCC Protocols.2003
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A2. Insulin Pellet Implantation Protocol
MATERIALS:
LinShin LinPlant Insulin Pellet
Rat anesthetic - Isoflurane
Ampicillin
Sterile water
1ml syringe with 25 g needle
10% providone-iodine solution
gauze (or swab)
Tissue forceps
Scalpel handle and blades (or scissors)
Silk suture
Needle drivers
EQUIPMENT:
IsofluoraneAnaesthetic Machine
Hair clippers
Heat lamp
Special Safety:
Must don lab coat and gloves before handling rodents. Any bite or scratch that breaks
the skin must be thoroughly scrubbed with soap and water (report to Occupational
Health and Safety).
Procedure:
Pellet implantation (for a rat):
1. Anesthetize the animal using the isofluorane machine by placing it in the

induction chamber. Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open
the stopcock valve so gas reaches the chamber. Keep in chamber until the animal
is unconscious.
2. Remove the animal and place its nose in the nose cone, reduce the isofluorane to

3% to maintain the plane of anesthesia.
3. Shave the area where the pellet is to be implanted.
4. Using gauze (or a swab), apply 10% providone-iodine solution to the skin,

followed by 70% ethanol, to disinfect the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% providone-iodine solution and insert it through the

puncture site to a depth of at least 2 cm.
7. Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse

with saline and insert into the subcutaneous region.

90

8. Use 1 pellet for the first 350g of body weight.
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 %

providone-iodine solution over the opening.
10. Close the incision by suturing.
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.

Pellet removal:
1. Anesthetize the animal as described above for implantation.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by

applying 10% providone-iodine solution followed by 70% ethanol.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the

location of the pellets.
4. Using forceps, remove the pellet. Some connective tissue may need to be cut away

using scissors. Discard the pellet.
5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.

References:
http://www.linshincanada.com
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A3. Intravenous Glucose Tolerance Test Protocol (Rat)
MATERIALS:
15 ml Falcon tube
D-glucose
Distilled water
0.2 um syringe filter
5 ml vacutainer
Lidocaine Cream
3 ml syringe
Restraining towel
Microcentrifuge tubes
Vaseline
27 G needles
30 G needles
Gauze squares
EQUIPMENT:
Mettler balance
Biological safety cabinet
Heat lamp with 175 watt bulb
Glucometer (Freestyle mini)
Timer

Special Safety:
Must don lab coat and gloves before handling rats. Any bite or scratch that breaks the
skin must be thoroughly scrubbed with soap and water (report to Occupational Health
and Safety).

PROCEDURE:
Fasting Rats:
1. Fast animals for 8-12 hours prior to the tolerance test
Glucose preparation:
1. On the morning of the IVGTT, dispense 5ml distilled water into a clean 15 ml

Falcon tube.
2. Weigh out 5 grams of D-glucose, and add it to the tube containing the sterile

water. Dissolve by vortexing to result in a 50% glucose solution.
3. In a biological safety cabinet, sterilize the glucose solution using a 0.2 um syringe

filter.
4. Transfer the sterile glucose solution to a new sterile 15mL Falcon tube.
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Intravenous Glucose Tolerance Test (IVGTT):
1. Place the cage containing the rat under a heat lamp. Remove the tube from the
cage, and provide water for the rat. Warm the rat in this manner for 10 minutes.
2. Remove the rat from the cage and scrub the tail using soap and water.
3. Measure and record the rat’s weight.
4. Obtain a baseline blood glucose reading from saphenous vein and collect a

baseline serum sample (keep blood sample on ice).
5. Return the rat to the cage and warm for an additional 20 minutes.
6. Place the rat’s tail in a container of warm tap water for 30-60 seconds.
7. One person should dry the tail and restrain the rat by wrapping it in a green drape

so the tail is exposed. Occlude the lateral tail vein by applying pressure.
8. Using a 3 ml syringe and a 27 G needle, a second person will draw up the 50%

glucose solution at a dose of 1g/kg (2 ml/kg). Locate the lateral tail vein and draw
back on the plunger to ensure that the needle is within the vein.
9. Release the occlusion while the glucose solution is injected. Draw back the

plunger a couple of times during the injection to ensure that the needle remains
located within the vein.
10. Start the timer and return the rat to its cage. Continue warming it for the duration

of the IVGTT.
11. Check and record the blood glucose values for the rat at 5, 10, 20, 30, 40, 50 and

60 minutes post glucose challenge. If by 60 minutes, the blood glucose value
hasn’t returned to baseline, continue to check every 30 minutes until it does so (up
to a maximum of 180 minutes).
12. Obtain a blood serum sample 10 minutes following D-glucose injection (store at

-70°C until insulin analyses).
13. Upon completion of the IVGTT, remove the rat from under the heat lamp and

return the tube to the cage. Place food on the wire lid of the cage, and ensure that
the rat has access to water.
14. Note on the cage card that an IVGTT has been performed.

Reference:
Straczkowski M et al, The effect of exercise training on glucose tolerance and skeletal
muscle triacylglycerol in rats fed with a high-fat diet. Diabetes and Metabolism
(2001) 21 p19.
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